$XBI $71.21 | +3.55%
Table of Contents:
Covid Updates
#NVAX -20% Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis
Pipeline Updates
#DTIL +17% Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022.
#NRIX +16.3% Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
#TGTX +7.3% TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting.
#LEGN +6.4% Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
#IMCR +6.1% Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma.
#PTCT +5.5% Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
#CYTK +3.7% Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
#ESPR +3.7% Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
#IMMP +2.3% Immutep posts Phase 2 data for lung cancer therapy to support late-stage studies
#GRCL +1.8% Gracell Biotechnologies Schedules Clinical Update Call After EHA2022
#IPHA +1.8% Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer.
#ALXO +1.6% ALX Oncology Announces Evorpacept Clinical Program Updates.
#IONS +0.8% Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients.
#APLT +0.8% Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia.
#SRNE +0.6% Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
#ICPT -7.2% INTERCEPT ANNOUNCES NEW CLINICAL TRIAL AND REAL-WORLD OUTCOMES DATA FOR OCALIVA IN PBC.
#AGLE -14.5% (6/2/22) Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#TPTX +118% Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
#IOVA +18.9% Iovance Biotherapeutics Up 16% After Insiders Buy Shares
#APTO -5.5% Aptose Presents Highlights from Corporate Update and KOL Event.
Posted by DV/FS
Comments